Who are Measles-mumps-rubella-varicella vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BCG solvent, Yellow Fever, Varicella Vaccine, yellow fever vaccine (YFV), mOPV1, Live Smallpox Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/measles-mumps-rubella-varicella-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Measles-mumps-rubella-varicella vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Measles-mumps-rubella-varicella vaccine (Measles-mumps-rubella-varicella vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Measles-mumps-rubella-varicella vaccine (Measles-mumps-rubella-varicella vaccine) — Sanofi Pasteur, a Sanofi Company. This vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, rubella, and varicella viruses by introducing attenuated (weakened) forms of all four viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Measles-mumps-rubella-varicella vaccine TARGET	Measles-mumps-rubella-varicella vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Live attenuated vaccine
BCG solvent	BCG solvent	Bandim Health Project	marketed	Live attenuated vaccine
Yellow Fever	Yellow Fever	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine
Varicella Vaccine	Varicella Vaccine	Novartis	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
yellow fever vaccine (YFV)	yellow fever vaccine (YFV)	PATH	marketed	Live attenuated vaccine
mOPV1	mOPV1	Aga Khan University	marketed	Live attenuated vaccine	Poliovirus type 1
Live Smallpox Vaccine	Live Smallpox Vaccine	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"	marketed	Live attenuated vaccine	Vaccinia virus antigens (envelope and intracellular proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Measles-mumps-rubella-varicella vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/measles-mumps-rubella-varicella-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab